165 related articles for article (PubMed ID: 34450632)
1. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Tempestilli M; D'Avolio A; De Nicolò A; Agrati C; Antinori A; Cicalini S
J Antimicrob Chemother; 2021 Nov; 76(12):3320-3322. PubMed ID: 34450632
[No Abstract] [Full Text] [Related]
2. Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches.
Martin C; Unal G; Plantier JC; Alessandri-Gradt E
J Antimicrob Chemother; 2022 Jul; 77(8):2305-2307. PubMed ID: 35488848
[No Abstract] [Full Text] [Related]
3. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
Bachelard A; Isernia V; Vallois D; Le Gac S; Chalal L; Landman R; Damond F; Descamps D; Yazdanpanah Y; Peytavin G; Ghosn J
J Antimicrob Chemother; 2021 Aug; 76(9):2484-2485. PubMed ID: 34109414
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Rodriguez CA; Natukunda E; Strehlau R; Venter EL; Rungmaitree S; Cunningham CK; Lalloo U; Kosalaraksa P; HellstrÖm E; Liberty A; McGrath EJ; Kaur M; Leisegang R; Hindman JT; Vieira VA; Kersey K; Cotton MF; Rakhmanina N; Gaur AH
Lancet HIV; 2024 May; 11(5):e300-e308. PubMed ID: 38621393
[TBL] [Abstract][Full Text] [Related]
7. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
[No Abstract] [Full Text] [Related]
8. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Gelé T; Chéret A; Castro Gordon A; Nkam L; Furlan V; Pallier C; Becker PH; Catalan P; Goujard C; Taburet AM; Gasnault J; Gouget H; Barrail-Tran A
J Antimicrob Chemother; 2021 Nov; 76(12):3280-3285. PubMed ID: 34508640
[TBL] [Abstract][Full Text] [Related]
10. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Lagoutte-Renosi J; Flammang M; Ducloux D; Bamoulid J; Royer PY; Lepiller Q; Clairet AL; Davani S; Muret P
J Chemother; 2022 May; 34(3):199-202. PubMed ID: 34180378
[TBL] [Abstract][Full Text] [Related]
11. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
[TBL] [Abstract][Full Text] [Related]
13. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Roa PE; Bazzi R
Int J STD AIDS; 2022 Jan; 33(1):97-98. PubMed ID: 34787026
[TBL] [Abstract][Full Text] [Related]
14. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
15. Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
Johnson TM; Rivera CG
Am J Health Syst Pharm; 2023 Feb; 80(4):180-181. PubMed ID: 36377971
[No Abstract] [Full Text] [Related]
16. Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML; Andreatta K; Acosta R; Martin H; Chang S; Martin R; White KL
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):433-440. PubMed ID: 34897227
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).
Imaz A; Tiraboschi JM; Niubó J; Martinez-Picado J; Cottrell ML; Domingo P; Chivite I; Negredo E; Schauer A; Van Horne B; Morenilla S; Urrea V; Silva-Klug A; Scévola S; Garcia B; Kashuba ADM; Podzamczer D
Clin Infect Dis; 2021 Oct; 73(7):e1991-e1999. PubMed ID: 32945851
[TBL] [Abstract][Full Text] [Related]
18. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
19. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
20. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
Hsu JY; Sun HY; Chen LY; Chang SY; Chuang YC; Huang YS; Su YC; Liu WC; Hung CC
J Glob Antimicrob Resist; 2024 Mar; 36():426-435. PubMed ID: 37923129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
